BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22389016)

  • 1. Acute megakaryoblastic leukemia and severe pulmonary fibrosis in a child with Down syndrome: successful treatment with ultra low-dose cytarabine using GATA1 mutation to monitor minimal residual disease.
    Moritake H; Yamada A; Kimoto Y; Sawa D; Shimonodan H; Nunoi H
    Am J Hematol; 2012 Apr; 87(4):447-50. PubMed ID: 22389016
    [No Abstract]   [Full Text] [Related]  

  • 2. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
    Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
    Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
    Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
    Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder.
    Xu G; Kato K; Toki T; Takahashi Y; Terui K; Ito E
    J Pediatr Hematol Oncol; 2006 Oct; 28(10):696-8. PubMed ID: 17023834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GATA1 mutations in myeloproliferative disorders: nomenclature standardization and review of the literature.
    Splendore A; Magalhães IQ; Pombo-de-Oliveira MS
    Hum Mutat; 2005 Oct; 26(4):390-2. PubMed ID: 16134163
    [No Abstract]   [Full Text] [Related]  

  • 6. GATA 1 mutations as clonal markers of minimal residual disease in acute megakaryoblastic leukemia of Down syndrome--a new tool with significant potential applications.
    Hitzler J; Zipursky A
    Leuk Res; 2005 Nov; 29(11):1239-40. PubMed ID: 15925405
    [No Abstract]   [Full Text] [Related]  

  • 7. GATA1 mutations in patients with down syndrome and acute megakaryoblastic leukaemia do not always confer a good prognosis.
    Ariffin H; Garcia JC; Daud SS; Ibrahim K; Aizah N; Ong GB; Chong LA; Mohamad Z
    Pediatr Blood Cancer; 2009 Jul; 53(1):108-11. PubMed ID: 19260099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [GATA1 analysis in myeloproliferative disorders associated to trisomy 21].
    Fuster Soler JL; Norton A; Galera Miñarro A; Bermúdez Cortés M; Llinares Riestra ME; Ortuño Giner F
    An Pediatr (Barc); 2011 Jan; 74(1):31-7. PubMed ID: 20870473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults.
    Kiyoi H; Yamaji S; Kojima S; Naoe T
    Leukemia; 2007 Mar; 21(3):574-6. PubMed ID: 17252020
    [No Abstract]   [Full Text] [Related]  

  • 10. [The role of GATA1 mutation in acute megakaryocytic leukemia].
    Ito E
    Rinsho Ketsueki; 2006 Nov; 47(11):1415-22. PubMed ID: 17176883
    [No Abstract]   [Full Text] [Related]  

  • 11. Down syndrome and GATA1-related transient leukemia.
    Sandoval C; Pine SR
    J Pediatr; 2007 Mar; 150(3):e34. PubMed ID: 17307526
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
    Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
    J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
    Roy A; Roberts I; Norton A; Vyas P
    Br J Haematol; 2009 Oct; 147(1):3-12. PubMed ID: 19594743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.
    Wechsler J; Greene M; McDevitt MA; Anastasi J; Karp JE; Le Beau MM; Crispino JD
    Nat Genet; 2002 Sep; 32(1):148-52. PubMed ID: 12172547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe TMD/AMKL with GATA1 mutation in a stillborn fetus with Down syndrome.
    Heald B; Hilden JM; Zbuk K; Norton A; Vyas P; Theil KS; Eng C
    Nat Clin Pract Oncol; 2007 Jul; 4(7):433-8. PubMed ID: 17597708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome.
    Malinge S; Izraeli S; Crispino JD
    Blood; 2009 Mar; 113(12):2619-28. PubMed ID: 19139078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prominent megakaryocytic dysplasia after regression of transient abnormal myelopoiesis associated with GATA-1 mutation.
    Anoop P; Atra A
    J Pediatr Hematol Oncol; 2012 Nov; 34(8):640. PubMed ID: 23007419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The molecular mechanism of leukemogenesis in Down syndrome-related acute megakaryocytic leukemia].
    Ito E; Toki T
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():136-40. PubMed ID: 17476742
    [No Abstract]   [Full Text] [Related]  

  • 19. Transient abnormal myelopoiesis in neonates: GATA get the diagnosis.
    Bombery M; Vergilio JA
    Arch Pathol Lab Med; 2014 Oct; 138(10):1302-6. PubMed ID: 25268193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mosaic Down syndrome-associated acute myeloid leukemia does not require high-dose cytarabine treatment for induction and consolidation therapy.
    Kudo K; Hama A; Kojima S; Ishii R; Morimoto A; Bessho F; Sunami S; Kobayashi N; Kinoshita A; Okimoto Y; Tawa A; Tsukimoto I
    Int J Hematol; 2010 May; 91(4):630-5. PubMed ID: 20237876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.